Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 April 2010Website:
http://www.codexis.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 28 min agoDividend
Analysts recommendations
Institutional Ownership
CDXS Latest News
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company's investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty.
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York.
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago.
WIX Q4 performance is likely to have benefited from an uptake of new products and improvement in the user base.
Codexis, Inc. (CDXS) Q3 2023 Earnings Call Transcript
REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place in Amsterdam, Netherlands and virtually October 30-November 1, 2023.
Codexis, Inc. is undergoing a significant restructuring to reduce costs, refocus its developmental efforts and streamline its organization. The company's ECO platform to provide enzymes for RNA therapeutics shows some potential, but the company's cash burn rate remains concerning. Insider purchases and consolidation of operations may indicate a turnaround, but previous insider selling this year raises concerns about management's commitment.
Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to Vaxcyte to focus on technology development, inducing cost savings, to extend its cash runway to mid-2026. The stock rises 7%.
What type of business is Codexis?
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
What sector is Codexis in?
Codexis is in the Healthcare sector
What industry is Codexis in?
Codexis is in the Biotechnology industry
What country is Codexis from?
Codexis is headquartered in United States
When did Codexis go public?
Codexis initial public offering (IPO) was on 22 April 2010
What is Codexis website?
https://www.codexis.com
Is Codexis in the S&P 500?
No, Codexis is not included in the S&P 500 index
Is Codexis in the NASDAQ 100?
No, Codexis is not included in the NASDAQ 100 index
Is Codexis in the Dow Jones?
No, Codexis is not included in the Dow Jones index
When does Codexis report earnings?
The next expected earnings date for Codexis is 02 August 2024